X

Evaluating Pharmacy Curriculum Outcomes Assessment and NAPLEX Performance, Phase 1

By: Zachary Piracha, PharmD Candidate c/o 2017 - BACKGROUND The pharmacy profession is constantly fortified by an ever-evolving process by…

eMAR

The Relationship Between Blueberry Supplementation and Memory Function

By: Amy Nguyen, PharmD Candidate c/o 2020 and Alex Chu, PharmD Candidate c/o 2019 - One of the most common…

eMAR

A Step in the Right Direction

By: Sal Monaco, PharmD Candidate c/o 2018 - In recent years, the state of California has remained at the forefront…

eMAR

FDA Approves Obiltoxaximab (Anthim®) Injection for Inhalational Anthrax

By: Alex Chu, Staff Writer - On March 21 2016, the Food and Drug Administration (FDA) approved obiltoxaximab (Anthim®), an…

eMAR

Carfentanil Poses New Threat of Epidemic in Local Communities

By: Gabrielle Flavoni, PharmD Candidate c/o 2018 - Drug diversion has always been a golden target for our nation’s law…

eMAR

Results of Largest Pharmacotherapy Smoking Cessation Trial Prompts Debate over Varenicline’s Black Box Warning

By: Nicollette Pacheco, PharmD Candidate c/o 2017 - It is an easy decision to include a black box warning on…

eMAR

New Metformin Labeling Change Mandated by the FDA

By: Jack (Hongkai) Bao, PharmD Candidate 2018 - Metformin is an oral anti-hyperglycemic agent of the biguanide class and is…

eMAR

Risk of Using Mislabeled and Unregulated Cannabidiol Products for Pain Management

By: Zachary Piracha, Pharm.D Candidate 2017 - The following account is a case report I was involved with during my…

eMAR

Brexpiprazole: A Novel Antipsychotic for Major Depressive Disorder and Schizophrenia

By: Nicollette Pacheco, Staff Editor [Graphics-focused] - Brexpiprazole (REXULTI®) is a novel atypical antipsychotic that was approved in July 2015…

eMAR

Medication Delivery: There’s an App for That

By:  Caitlyn Cummings, Pharm.D. and Maria Marzella Mantione, Pharm.D., CGP, FAPhA - From ordering food to requesting transportation, we trust…

eMAR